Mayne Pharma Group Limited (Premium)



Ticker code: ASX:NAB

ASX:NAB Red Flags & Risk Indicators
⚠️ RED FLAGS: 4 identified

  • Low Operating Margin
  • Falling Earnings
  • More Net Debt Than Equity
  • High Relative Valuation

Income Statement
Revenue 2024 Per Share Revenue 2025e Per Share Revenue 2026e Per Share Revenue 24 to 25e [%] Revenue 25e to 26e [%] EBITDA 2024 Per Share EBITDA 2025e Per Share EBITDA 2026e Per Share EBITDA 24 to 25e [%] EBITDA 25e to 26e [%]
7.44369 None None None None None None None None None
ASX:NAB Revenue Per Share (2012–2027)

Mayne Pharma Group Limited (ASX:NAB) Revenue Chart 2012–2027
ASX:NAB Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) Per Share (2012–2027)

Mayne Pharma Group Limited (ASX:NAB) EBITDA Chart 2012–2027
ASX:NAB Normalised Earnings Per Share (EPS) (2012–2027)
Mayne Pharma Group Limited (ASX:NAB) Normalised EPS Chart (2012–2027)

Valuation
Price To Sales Price To Book PER 2023 PER 2024 13Y Median PER Low PER 2025e 13Y Median PER High PER 2026e Last Updated
6.6 2.1 18.8 19.2 11.5 19.4 14.4 19.0 23/7/25
ASX:NAB Yearly Price Earnings Ratio (PER) Highs and Lows
Mayne Pharma Group Limited (ASX:NAB) PER Highs and Lows (2012–2027)
ASX:NAB Weekly Price Chart with Average True Range (ATR) Trailing Stop (10-Year View)
Mayne Pharma Group Limited (ASX:NAB) 10-Year Weekly ATR Trailing Stop Price Chart


Leave a Reply

Your email address will not be published. Required fields are marked *